Inflation Reduction Act Tool
This tool is designed to assess whether a launched or investigational drug within the US market is likely to become
subject to pricing measures introduced by the Inflation Reduction Act (IRA) from 2022 over the coming years.
It is supported by a complimentary white paper, which is based on groupH analysis and insights
from internal and external US market access experts.